You are here:

Archived: trastuzumab emtansine (Kadcyla)

Advice

following a full submission assessed under the end of life / orphan process:

trastuzumab emtansine (Kadcyla ®) is not recommended for use within NHS Scotland.

Indication under review: as a single agent, for the treatment of adult patients with human epidermal growth factor type 2 (HER2)-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:
• Received prior therapy for locally advanced or metastatic disease, or
• Developed disease recurrence during or within six months of completing adjuvant therapy.

In a randomised phase III open-label study, trastuzumab emtansine (Kadcyla®) conferred a median six months additional survival benefit compared with an active comparator.

The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient to gain acceptance by SMC.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
 

Drug Details

Drug Name: trastuzumab emtansine (Kadcyla)
SMC Drug ID: 990/14
Manufacturer: Roche
Indication: as a single agent, for the treatment of adult patients with human epidermal growth factor type 2 (HER2)-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: Received prior therapy for locally advanced or metastatic disease, or, developed disease recurrence during or within six months of completing adjuvant therapy
BNF Category:
Sub Category: 8.1 Cytotoxic drugs
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 13 October 2014

Current Advice

Resubmission 10 April 2017

Back